Results 61 to 70 of about 4,984,276 (289)

Advances in myelofibrosis: a clinical case approach

Haematologica, 2013
Primary myelofibrosis is a member of the myeloproliferative neoplasms, a diverse group of bone marrow malignancies. Symptoms of myelofibrosis, particularly those associated with splenomegaly (abdominal distention and pain, early satiety, dyspnea, and ...
John O. Mascarenhas, Attilio Orazi, Kapil N. Bhalla, Richard E. Champlin, Claire Harrison, Ronald Hoffman   +5 more
doaj   +1 more source

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model

Blood Cancer Journal, 2019
Among 1306 patients with primary myelofibrosis (PMF), we sought to identify risk factors that predicted leukemic transformation (LT) in the first 5 years of disease and also over the course of the disease.
Rangit R. Vallapureddy, M. Mudireddy, D. Penna, T. Lasho, C. Finke, C. Hanson, R. Ketterling, K. Begna, N. Gangat, A. Pardanani, A. Tefferi   +10 more
semanticscholar   +1 more source

Transforming growth factor β‐mediated micromechanics modulates disease progression in primary myelofibrosis

Journal of Cellular and Molecular Medicine, 2020
Primary myelofibrosis (PMF) is a Ph‐negative myeloproliferative neoplasm (MPN), characterized by advanced bone marrow fibrosis and extramedullary haematopoiesis.
Patric Teodorescu, Sergiu Pasca, A. Jurj, Grigore-Aristide Gafencu, J. Jóelsson, Sonia E Selicean, C. Moldovan, R. Munteanu, Anca Onaciu, A. Țigu, Mihail Buse, Alina-Andreea Zimta, R. Știufiuc, B. Petrushev, Minodora Desmirean, D. Dima, C. Vlad, J. Bergthórsson, C. Berce, S. Ciurea, G. Ghiaur, C. Tomuleasa   +21 more
semanticscholar   +1 more source

The Regulatory Role of Iron Transporter SLC39A13 in Liver Fibrosis

Advanced Science, EarlyView.
SLC39A13/ZIP13, a newly discovered intracellular iron transporter, delivers iron to the ER/Golgi to catalyze procollagen hydroxylation during collagen maturation. Here, we systematically characterize the cell type‐specific functions of ZIP13 across distinct hepatic cell populations, and identify hepatic stellate cell‐specific ZIP13 as a promising and ...
Shanshan Guo, Yalin Wang, Binyu Lu, Yu Zhang, David M. Frazer, Bing Zhou   +5 more
wiley   +1 more source

A case of mistaken identity: When lupus masquerades as primary myelofibrosis

SAGE Open Medical Case Reports, 2013
Introduction: Autoimmune myelofibrosis is an uncommon hematologic disease characterized by anemia, bone marrow myelofibrosis, and an autoimmune feature. Myelofibrosis is often associated with other conditions, including infections, nutritional/endocrine ...
Edy Hasrouni, Heesun J Rogers, Ali Tabarroki, Valeria Visconte, Fabiola Traina, Manuel Afable, Mikkael A Sekeres, Jaroslaw P Maciejewski, Ramon V Tiu   +8 more
doaj   +1 more source

Primary Hypertrophic Osteoarthropathy With Myelofibrosis

Cureus, 2022
Primary hypertrophic osteoarthropathy (PHO) is a rare autosomal recessive inherited multi-system disorder characterized by a triad of pachydermia, periostosis, and clubbing. PHO was revealed to be caused by the HPGD gene producing 15-prostaglandin dehydrogenase and the SLCO2A1 gene expressing one kind of prostaglandin transporter.
Yousaf, Muhammad, Khan, Rubina, Akram, Zaineb, Chaudhry, Qammar U, Iftikhar, Raheel   +4 more
openaire   +2 more sources

The Calreticulin gene and myeloproliferative neoplasms [PDF]

, 2016
The Philadelphia negative myeloproliferative neoplasms include polycythaemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF).
Clinton, Aoibhinn, McMullin, Mary Frances   +1 more
core   +1 more source

A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo

American Journal of Hematology, EarlyView.
ABSTRACT Calreticulin (CALR) mutations are prevalent in 20%–30% of patients with BCR::ABL1‐negative myeloproliferative neoplasms (MPN). Mutant calreticulin (mutCALR), presented by the thrombopoietin receptor (MPL, also known as TPOR or CD110) on the surface of the disease‐initiating MPN progenitors, represents an ideal target for curative ...
Shengen Xiong, Tamara Wais, Cecilia Varga, Christina Schueller, Sarada Achyutuni, Robert Kralovics   +5 more
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Clinical features and therapeutic outcome of 30 patients diagnosed with primary myelofibrosis at the national center of hematology

مجلة كلية الطب, 2015
Background: Primary myelofibrosis is characterized by clonal expansion of hematopoietic stem cell with a non-reactive clonal proliferation of fibroblasts and bone marrow fibrosis, which occurs at an extramedullary hematopoiesis.
Alaa F. Alwan
doaj   +1 more source